RIP Links TLR4 to Akt and Is Essential for Cell Survival in Response to LPS Stimulation

Marina S. Vivarelli, Douglas McDonald, Mendy Miller, Nicole Cusson, Michelle Kelliher, and Raif S. Geha

Introduction

Receptor-interacting protein (RIP) is a death domain kinase that associates with tumor necrosis factor receptor (TNFR)1 (1). RIP binds TNFR-associated factor (TRAF)2 (2) and is essential for TNF-induced NFkB activation and protection from cell death (3). RIP also interacts with IkB kinase (IKK)γ (NEMO) (4), which plays a critical role in activation of the IKK complex, IkB phosphorylation, and NFkB activation and expression of antiapoptotic genes. RIP interacts with TRAF6 through the p62 adaptor protein to potentiate the activation of the IKK complex by TRAF6 (5).

RIP−/− mice die at 1–3 d of age with apoptosis of lymphoid and adipose tissues (3). Their viability is partially rescued by breeding on the TNFR1−/− background (6). RIP−/− murine embryonic fibroblasts (MEFs) fail to activate NFkB in response to TNF-α and have enhanced sensitivity to TNF-induced cell death (3). RIP−/− thymocytes show increased death, which is rescued by breeding on the TNFR2−/− background in an NFkB-independent manner (6).

Ligation of CD40 or TLR4 on B cells leads to proliferation, isotype switching and up-regulation of the surface expression of costimulatory molecules (7). B cell activation via CD40 requires binding of TRAF2 and/or TRAF6 (8). Binding of TRAF6 controls affinity maturation and the generation of long-lived plasma cells (9). TLR4 signaling by LPS activates two major signal transduction pathways. The first is mediated by MyD88–IRAK–TRAF6 and leads to the activation of IKK, JNK, and p38. The second, MyD88-independent pathway, is mediated by TRAM–TRIF–IRF3 and leads to the expression of type I interferons and up-regulation of expression of costimulatory molecules (10). Both pathways are required for optimal activation of NFkB and induction of NFkB-dependent genes (11, 12) and may intersect at the level of TRAF6, as TRIF interacts with TRAF6 (13).

Other members of the RIP family include RIP2, which has been implicated in TLR signaling (14, 15), RIP3, which is not essential for NFkB activation by Toll receptors (16), and RIP4, which plays an essential role in B cell development and activation (17). The fact that RIP interacts with TRAF2 and TRAF6 prompted us to investigate the potential role of RIP in CD40 and TLR4 signal transduction. To address this question, we took advantage of the availability of RIP−/− mice.

Materials and Methods

Mice. Previously generated RIP+/−/TNFR1−/− mice (6) were crossed to obtain RIP−/−/TNFR1−/− double mutant mice. The pups were chosen at 2–5 d of age as the runts of the litter.

Abstract

Receptor-interacting protein (RIP) has been reported to associate with tumor necrosis–associated factor (TRAF)2 and TRAF6. Since TRAF2 and TRAF6 play important roles in CD40 signaling and TRAF6 plays an important role in TLR4 signaling, we examined the role of RIP in signaling via CD40 and TLR4. Splenocytes from RIP−/− mice proliferated and underwent isotype switching normally in response to anti-CD40–IL-4 but completely failed to do so in response to LPS–IL-4. However, they normally up-regulated TNF-α and IL-6 gene expression and CD54 and CD86 surface expression after LPS stimulation. RIP−/− splenocytes exhibited increased apoptosis and impaired Akt phosphorylation after LPS stimulation. These results suggest that RIP is essential for cell survival after TLR4 signaling and links TLR4 to the phosphatidylinositol 3 kinase–Akt pathway.

Key words: NFkB • IkB • p38 MAP kinase • IL-6 • TNF-α

The Journal of Experimental Medicine
RIP\(^{+/+}\) homozygous and RIP\(^{+-}\) heterozygous littermates were used as controls. Genotype was confirmed by PCR as described previously (6). Same strain (129 Svev/C57Bl6), age-matched, WT controls were purchased from Jackson Laboratories. Experiments and animal care were performed according to institutional guidelines.

**FACS\(^{\circledast}\) Analysis.** Single cell suspensions were stained with FITC-PE-conjugated mAbs or with annexin-FITC as described previously (8). Quadrants were drawn according to isotype control staining. FITC- or PE-conjugated mAbs used in these studies were: anti-CD3, anti-B220, anti-IgM, anti-CD86, and anti-CD54 (BD Biosciences). For CD54 and CD86 expression, purified splenic B cells (>80% B220\(^{+}\)) obtained by positive selection using MACS CD45R (B220) MicroBeads (Miltenyi Biotec) were cultured for 24 h with complete medium (RPMI 1640 from GIBCO BRL supplemented with 10% FBS from Sigma-Aldrich and 1% penicillin/streptomycin from Life Technologies), sCD40L (1:20 dilution of supernatants from muCD40L:muCD80-transfected J558L cells), or LPS (10 \(\mu g/ml\); Sigma-Aldrich).

**In Vitro Proliferation and Isoy Type Switching of B Cells.** For proliferation, spleen cells or purified B cells (0.7 \(\times\) 10\(^6\)/ml) were cultured in complete medium alone or in the presence of anti-CD40 (1 \(\mu g/ml\), HM40-3; BD Biosciences) with or without IL-4 (25 ng/ml; R&D Systems), LPS (10 \(\mu g/ml\) with or without IL-4, and CpG ODN1826 (10 \(\mu M\); Invivogen) for 72 h, pulsed with 1 \(\mu Ci\) [\(\text{H}\)]thymidine for an additional 16 h, harvested, and scintillation was counted. For isotype switching, spleen cells (0.5 \(\times\) 10\(^6\)/ml) were cultured in complete medium alone or in the presence of IL-4, anti-CD40 alone or with IL-4, LPS alone or with IL-4. Supernatants were collected after 6 d, and immunoglobulins were assayed by ELISA as described previously (8).

**RT-PCR for \(\alpha\) and \(\gamma\)1 Germ Line Transcripts, Activation-induced Deaminase, b2-Microglobulin, and mTLR4.** RNA was extracted from 72-h cultured splenocytes using TRIzol (Invitrogen) and was reverse transcribed using Superscript II RT (Invitrogen). PCR reactions for \(\alpha\) and \(\gamma\)1 germ line transcripts (GLTs), activation-induced deaminase (AID), and b2-microglobulin and for mTLR4 were performed as described previously on various dilutions of cDNA to ensure that the products measured were in the linear range (8, 18). Amplified products were separated in 1% agarose gels and stained with ethidium bromide.

**Real-Time PCR for TNF-\(\alpha\) and IL-6 Gene Expression.** RNA was prepared from splenocytes cultured for 16 h with medium or LPS (10 \(\mu g/ml\)) as above. Real-time quantitative RT-PCR reactions were run on an ABI Prism 7700 (Applied Biosystems) sequence detection system platform. Sybr green chemistry was used for TNF-\(\alpha\) (TNF-\(\alpha\) forward, 5’-ccacagttgagcaac-3’ and TNF-\(\alpha\) reverse, 5’-cagctctgccctgaa-3’) and \(\beta\)-actin. For IL-6, Taqman primers with FAM-labeled probe (Applied Biosystems) were used. The relative gene expression among the different samples was determined using the method described by Pfaffl (19). Melt curve analysis was performed for products detected by sybr green to ensure purity of product.

**Western Blotting.** Cell lysates were obtained from splenocytes (0.5 \(\times\) 10\(^6\) cells/condition) suspended in medium containing 1% FCS and stimulated with LPS (10 \(\mu g/ml\)) or CpG ODN1826 (3 \(\mu M\)) for 15 min. Blots were incubated with antibodies specific for phospho-Akt, Akt (Becton Dickinson), phospho-p38, or phospho-IkB (Cell Signaling) followed by horseradish peroxidase–conjugated goat anti-rabbit or goat anti-mouse antibodies (Becton Dickinson). Blots were scanned and OD of bands quantitated using NIH Image 16.2 software. Fold induction was calculated as the ratio of OD of the phosphoproteins in lysates of LPS-stimulated to unstimulated cells, each normalized for the OD of their Akt band.

**Results and Discussion.**

**RIP\(^{-/-}\)/TNFR1\(^{-/-}\) Mice Have Normal Percentages of B Cells in Their Spleens.** Splenocytes were taken from RIP\(^{-/-}\)/TNFR1\(^{-/-}\) pups and RIP\(^{+/+}\)/TNFR1\(^{-/-}\) littermates. Because in all experiments splenocytes from RIP\(^{+/+}\)/TNFR1\(^{-/-}\) and RIP\(^{+/+}/\)TNFR1\(^{-/-}\) littermates behaved identically, we present data only on RIP\(^{+/+}/\)TNFR1\(^{-/-}\) controls. Total number of splenocytes was comparable between RIP\(^{+/+}/\)TNFR1\(^{-/-}\) and age-matched WT controls but was significantly lower in the double mutant mice (6.2 \(\times\) 10\(^6\) \(\pm\) 2 versus 20 \(\times\) 10\(^6\) \(\pm\) 6 in littermate controls and 2 \(\times\) 10\(^6\) \(\pm\) 8 in WT controls). The three- to fourfold decrease in splenocyte number in RIP\(^{-/-}/\)TNFR1\(^{-/-}\) pups is commensurate with the threefold reduction in the weight of these pups (3).

The percentages of B cells, B cell subsets, and T cells were assessed by FACS\(^{\circledast}\) analysis (Fig. 1). The percentage of B220\(^{+}\) cells was comparable in spleens from RIP\(^{-/-}/\)TNFR1\(^{-/-}\) and RIP\(^{+/+}/\)TNFR1\(^{-/-}\) littermates. This is consistent with normal B cell development in RIP\(^{-/-}\) embryos (3) and with the observation that reconstitution of irradiated WT and RAG1\(^{-/-}\) mice with fetal liver cells from RIP\(^{-/-}\) embryos results in normal B cell development (6). More importantly, the percentages of mature B220\(^{+}\)/IgM\(^{+}\) cells were comparable in splenocytes...
from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> pups and RIP<sup>+/+</sup>/TNFR1<sup>−/−</sup> littermates. The decreased percentage of CD3<sup>+</sup> cells in spleens of RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> pups is consistent with the deleterious effect of RIP disruption on thymocyte development (6). Spleen cell populations of RIP<sup>+/+</sup>/TNFR1<sup>−/−</sup> littermates were comparable to those present in age-matched WT controls (unpublished data). This is consistent with the observation that TNFR1<sup>−/−</sup> mice have normal B cell development (20).

**RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> B Cells Fail To Proliferate Specifically in Response to LPS.** Splenocytes from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> mice proliferated normally in response to anti-CD40 + IL-4, whereas they completely failed to proliferate in response to LPS. This failure was not rescued by IL-4 (Fig. 2 A). This result was confirmed in two separate experiments performed on purified B cells (unpublished data), suggesting that the failure to proliferate to LPS reflects an intrinsic defect in B cells. The failure of B cells from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> to proliferate to LPS was not simply due to lack of TLR4 expression. RT-PCR analysis of mRNA revealed TLR4 expression in purified B cells from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> and RIP<sup>+/+</sup>/TNFR1<sup>−/−</sup> littermates (Fig. 2 B). TLR9 engagement by the ligand CpG ODN 1826 also causes B cell proliferation (21). TLR9-induced proliferation was significantly impaired in splenocytes from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> mice (Fig. 2 C).

**RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> B Cells Have Severely Impaired IgG1 and IgE Isotype Switching in Response To LPS 1 IL-4.** To further assess the response of B cells from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> pups to LPS, we examined the ability of splenocytes from these mice and littermate controls to secrete IgG1 and IgE in response to stimulation with LPS + IL-4 or anti-CD40 + IL-4. Splenocytes from the double mutant mice secreted normal amounts of IgG1 and IgE in response to anti-CD40 + IL-4 but were severely impaired in their ability to secrete IgG1 and IgE in response to LPS + IL-4 (Fig. 2, D and E). The molecular events involved in isotype switching in naïve B cells include expression of GLTs and expression of the gene for AID, followed by deletional switch recombination and expression of mature post switch transcripts (7). LPS induces expression of the AID gene and synergizes with IL-4 in inducing the expression of C<sub>γ</sub>1 and C<sub>ε</sub> GLTs to result in isotype switching to IgG1 and IgE. The ability of LPS to activate these events in B cells from RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> peps and littermate controls was examined. LPS by itself induced AID gene expression in RIP<sup>+/+</sup>/TNFR1<sup>−/−</sup> B cells and synergized with IL-4 to induce C<sub>γ</sub>1 and C<sub>ε</sub> GLTs in these cells (Fig. 2 F). In contrast, LPS failed to induce detectable AID gene expression in RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> B cells and synergized poorly with IL-4 in inducing expression of C<sub>γ</sub>1 GLT and AID in these cells. LPS also failed to synergize with IL-4 in inducing detectable C<sub>ε</sub> GLT in RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> B cells. The defect in isotype switching of RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> B cells in response to LPS is not due to a generalized defect in these cells because CD40 ligation synergized with IL-4 to induce expression of C<sub>γ</sub>1 GLT, C<sub>ε</sub> GLT, and AID in RIP<sup>−/−</sup>/TNFR1<sup>−/−</sup> pups that was comparable to that observed in littermate controls. Since LPS induction of isotype switching in B cells has been
shown to be division linked (22), the failure of RIP-deficient B cells to undergo isotype switching in response to LPS may reflect their failure to proliferate.

**LPS Induction of TNF-α and IL-6 Expression Is Normal in RIP−/−/TNFR1−/− Splenocytes.** LPS stimulation of splenocytes induces the expression of several NFκB-dependent genes that include IL-6 and TNF-α, which are primarily expressed in macrophages and dendritic cells (23). LPS up-regulated IL-6 and TNF-α mRNA expression in splenocytes from RIP−/−/TNFR1−/− mice to an extent that was equivalent to that induced in splenocytes from RIP−/−/TNFR1−/− littermates (Fig. 3, A and B). This suggests that RIP is not essential for LPS-induced NFκB activation and is consistent with previous observations that LPS and IL-1 induce a normal NFκB response in RIP−/− thymocytes and MEFs (reference 3 and Fig. S1, available at http://www.jem.org/cgi/content/full/jem.20040446/DC1). In contrast, RIP2 has been shown to be important for LPS activation of NFκB and induction of IL-6 and TNF-α gene expression (14, 15).

**Up-regulation of CD54 and CD86 Surface Expression Is Normal in RIP−/−/TNFR1−/− B Cells.** LPS and CD40 ligation up-regulate the expression of several surface markers on B cells including the adhesion molecule CD54 and the co-stimulatory molecule CD86 (25). CD54 and CD86 surface expression was measured by FACS analysis of splenocytes from RIP−/−/TNFR1−/− and RIP−/−/TNFR1−/− B220+ cells stimulated with LPS or sCD40L. Similar results were obtained from two independent experiments.

**Figure 3.** Cytokine gene expression. Induction of mRNA for IL-6 (A) and TNF-α (B) by LPS in RIP−/−/TNFR1−/− pups (n = 3) and RIP−/−/TNFR1−/− controls (n = 3). Values show the fold induction over unstimulated control splenocytes cultured with medium as determined by real-time PCR. (C) Up-regulation of CD86 and CD54 expression on B cells. B220+ cells from RIP−/−/TNFR1−/− and RIP−/−/TNFR1−/− mice were left unstimulated (green) or were stimulated for 24 h with sCD40L (blue) or LPS (red). Similar results were obtained in four independent experiments (one using purified B cells).

**Figure 4.** Apoptosis and expression of Akt after LPS stimulation of splenocytes from RIP−/−/TNFR1−/− pups and RIP−/−/TNFR1−/− littermates. (A) Annexin V–FITC and B220–PE staining at 0, 16, and 96 h of splenocytes cultured with medium or LPS. Analysis was performed by gating on B220+ cells. Similar results were obtained in two separate experiments. (B) Akt, IκB, and p38 phosphorylation after stimulation of RIP−/−/TNFR1−/− and RIP−/−/TNFR1−/− splenocytes with LPS (n = 4) or CpG ODN 1826 (n = 2). Lysates were probed with Akt as loading control. (C) Fold induction of Akt, IκB, and p38 phosphorylation after LPS stimulation (n = 4) *P < 0.05.
(ICAM-1) and the costimulatory molecule CD86 (B7.2) (24). The TRIF–IRF3 type I interferon pathway is essential for the up-regulation by LPS of the costimulatory molecule CD86, whose promoter contains STAT sites that are potential targets of type I interferon–activated STATs but no NFkB sites (25). LPS stimulation of purified splenic B cells caused comparable up-regulation in the surface expression of CD54 and CD86 on B cells from RIP−/−/TNFR1−/− and RIP+/+/TNFR1−/− littermates (Fig. 3 C). B cells from RIP−/−/TNFR1−/− pups also normally up-regulated CD54 and CD86 expression in response to CD40 ligation. These results suggest that TLR4 signaling via the TRAM–TRIF–IRF3 pathway is preserved in RIP-deficient B cells.

**RIP Is Essential for Cell Survival After LPS Stimulation.** The observation that relatively early events after TLR4 signaling, e.g., up-regulation of surface markers and cytokine gene expression, were preserved, whereas later events, e.g., proliferation and isotype switching, were severely impaired in RIP-deficient splenocytes prompted us to examine the survival of these cells after sTLR4 ligation. Splenocytes in RIP-deficient splenocytes were severely impaired gene expression, were preserved, whereas later events, e.g., TLR4 signaling via the TRAM–TRIF–IRF3 pathway is also normally up-regulated CD54 and CD86 expression in TNFR1 (27). We used a phosphospecific antibody to examine Akt phosphorylation after LPS stimulation in RIP−/−/TNFR1−/− (26). More importantly, p85α-deficient B cells have impaired proliferation and increased apoptosis after LPS stimulation (27). We used a phosphospecific antibody to examine Akt phosphorylation after LPS stimulation in RIP−/−/TNFR1−/− splenocytes and control RIP+/+/TNFR1−/− splenocytes. LPS stimulation caused Akt phosphorylation in RIP+/+/TNFR1−/− splenocytes. In contrast, LPS induced virtually no Akt phosphorylation in RIP−/−/TNFR1−/− splenocytes (Fig. 3, B and C; n = 4). The decrease in Akt phosphorylation was specific because LPS induced normal phosphorylation of IkB and p38 in these cells (Fig. 3, B and C; n = 4). RIP−/−/TNFR1−/− splenocytes also had severely impaired Akt phosphorylation after CpG stimulation, but CpG induced IkB and p38 phosphorylation in these cells (Fig. 3 B; n = 2). These results suggest that RIP links TLR4 and TLR9 signaling to PI3 kinase activation. Analysis of Akt phosphorylation in subpopulations of purified cells was precluded by the decreased splenic cellularity and young age of RIP−/−/TNFR1−/− pups.

LPS-induced PI3 kinase activation is dependent on TAK1 (28), which interacts with RIP (29). Our data suggests that RIP is essential for TAK1-dependent TLR4 and TLR9 activation of PI3 kinase. The role of RIP in Akt activation by other TLR ligands and the exact molecular link between RIP and Akt remain to be elucidated. Although our data on splenocytes and MEFs suggests that RIP is not essential for TLR4 activation of NFkB, recent work indicates that RIP interacts with TRIF and is important for NFkB activation by TLR3 (30), as it is for NFkB activation by TNFR1. This suggests that RIP plays different roles in signaling by individual TLRs.

We wish to thank S. Brodeur, H. Jabara, E. Castigli, P. Bryce, A.G. Ugazio, and M. Castello for their invaluable help.

This work was supported by National Institutes of Health grant AI51136 and by a grant from the March of Dimes.

The authors have no conflicting financial interests.

Submitted: 8 March 2004
Accepted: 18 June 2004

---

**References**

1. Stanger, B.Z., P. Leder, T.H. Lee, E. Kim, and B. Seed. 1995. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:513–523.

2. Liu, Z.G., H. Hsu, D.V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 87:565–576.

3. Kellihier, M.A., S. Grimm, Y. Ishida, F. Kuo, B.Z. Stanger, and P. Leder. 1998. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 8:297–303.

4. Zhang, S.Q., A. Kovalenko, G. Cantarella, and D. Wallach. 2000. Recruitment of the IKB signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 12:301–311.

5. Sanz, I., M.T. Diaz-Meco, H. Nakano, and J. Moscat. 2000. The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J. 19: 1576–1586.

6. Casson, N., S. Oikemus, E.D. Kilpatrick, L. Cunningham, and M. Kellihier. 2002. The death domain kinase RIP protects thymocytes from tumor necrosis factor receptor type 2-induced cell death. J. Exp. Med. 196:15–26.

7. Manis, J.P., M. Tian, and F.W. Alt. 2002. Mechanism and control of class-switch recombination. Trends Immunol. 23:
9. Ahonen, C., E. Manning, L.D. Erickson, B. O’Connor, E.F. Lind, S.S. Pullen, M.R. Kehry, and R.J. Noelle. 2002. The CD40-independent toll-like receptor signaling pathway. Science. 301:640–643.

10. Takeda, K., and S. Akira. 2003. Toll receptors and pathogen resistance. Cell. Microbiol. 5:143–153.

11. Kawai, T., O. Adachi, T. Ogawa, K. Takeda, and S. Akira. 1999. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity. 11:115–122.

12. Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama, M. Okabe, K. Takeda, and S. Akira. 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301:640–643.

13. Sato, S., M. Sugiyama, M. Yamamoto, Y. Watanabe, T. Kawai, K. Takeda, and S. Akira. 2003. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171:4304–4310.

14. Kobayashi, K., N. Inohara, L.D. Hernandez, J.E. Galan, G. Nunez, C.A. Janeway, R. Medzhitov, and R.A. Flavell. 2002. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature. 416:194–199.

15. Chin, A.I., P.W. Dempsey, K. Bruhn, J.F. Miller, Y. Xu, and G. Cheng. 2002. Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature. 416:190–194.

16. Newton, K., X. Sun, and V.M. Dixit. 2004. Kinase RIP3 is dispensable for normal NF-kappa B signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol. Cell. Biol. 24:1464–1469.

17. Cariappa, A., L. Chen, K. Haider, M. Tang, E. Nebelitskiy, S.T. Moran, and S. Pillai. 2003. A catalytically inactive form of protein kinase C-associated kinase/receptor interacting protein 4, a protein kinase C beta-associated kinase that mediates NF-kappa B activation, interferes with early B cell development. J. Immunol. 171:1875–1880.

18. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. Kitamura, A. Kosugi, M. Kimoto, and K. Miyake. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3:667–672.

19. Pfaff, M.W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45.

20. Le Hir, M., H. Bluethmann, M.H. Kosco-Vilbois, M. Muller, F. di Padova, M. Moore, B. Ryffel, and H.P. Eugster. 1996. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J. Exp. Med. 183:2367–2372.

21. Krieg, A.M., A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:546–549.

22. Deenick, E.K., J. Hasbold, and P.D. Hodgkin. 1999. Switching to IgG3, IgG2b, and IgA is division linked and independent, revealing a stochastic framework for describing differentiation. J. Immunol. 163:4707–4714.

23. Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. Cell. 109:S81–S96.

24. Bishop, G.A., and B.S. Hostager. 2001. Signaling by CD40 and its mimics in B cell activation. Immunol. Rev. 183:2367–2372.

25. Fruman, D.A., S.B. Snapper, C.M. Yballe, L. Davidson, J.Y. Yu, F.W. Alt, and L.C. Cantley. 1999. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science. 283:393–397.

26. Irie, T., T. Muta, and K. Takeda. 2000. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Lett. 467:160–164.

27. Han, K.J., X. Su, L.G. Xu, L.H. Bin, J. Zhang, and H.B. Shu. 2004. Mechanisms of TRIF-induced ISRE and NF-kappa B activation and apoptosis pathways. J Biol Chem. 279:15652–12666.

28. Meylan, E., K. Burns, K. Hofmanna, V. Blancheteau, F. Martinez, M. Kelliber, and J. Tschopp. 2004. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat. Immunol. 5:503–507.